Jianhong Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jianhong Shen has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Qi Yao
Department of Neurosurgery, Affiliated Hospital of Nantong University
5 shared publications- Riyun Yang
Medical Morphology Laboratory, Medical School of Nantong University
4 shared publications Suyan Chang
Medical Morphology Laboratory, Medical School of Nantong University
4 shared publicationsSiying Chen
Medical Morphology Laboratory, Medical School of Nantong University
3 shared publicationsChenlong Li
Department of Neurosurgery, Affiliated Hospital of Nantong University, 226001 Nantong, Jiangsu, China
2 shared publicationsJian Chen
Department of Neurosurgery, Affiliated Hospital of Nantong University, Medical School of Nantong University , Nantong, Jiangsu 226001
2 shared publications
Latest Publications
- 23 August 2026
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- p. 1-37
Tissue engineering scaffolds for the spinal cord: recent advances and future prospects
1. Spinal cord injury (SCI) is a severe neurological condition. It is often caused by accidental trauma, falls, tumors, infections, and other factors, leading to various motor, sensory, and autonom...
- 23 August 2026
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- p. 1-37
Tissue engineering scaffolds for the spinal cord: recent advances and future prospects
1. Spinal cord injury (SCI) is a severe neurological condition. It is often caused by accidental trauma, falls, tumors, infections, and other factors, leading to various motor, sensory, and autonom...
- Open Access
- 22 January 2026
- Published by Oxford University Press (OUP) in Regenerative Biomaterials
- Vol. 13, rbag059
Dual-peptide engineered macrophage membrane biomimetic nanosystem via targeting Rg1 delivery for traumatic brain injury therapy
Traumatic brain injury (TBI) induces a detrimental inflammatory microenvironment at the lesion site, which, together with neuronal death and loss, leads to neurological dysfunction. The blood–brain barrier (BBB) further impedes intracerebral drug delivery, posing a major challenge for post-TBI therapy. To overcome this, we developed a brain-targeted biomimetic nanosystem (R/T-MaM-NPs) using an engineered dual-peptide-modified macrophage membrane (MaM). This system encapsulates neuroprotective ginsenoside Rg1 into poly (lactic-co-glycolic acid)-based nanoparticles (NPs). RAW264.7 macrophages were engineered to co-express targeting peptides (RVG and T7) on their membranes; the derived R/T-MaM was then coated onto NPs. The MaM coating conferred high biocompatibility and biosafety, enabling R/T-MaM-NPs to reduce immune clearance and prolong systemic circulation. By leveraging the intrinsic inflammatory chemotaxis of MaM and dual-peptide targeting, the integrated system promoted traversal across the BBB and subsequent accumulation around the cerebral lesion, thereby inducing the transdifferentiation of reactive astrocytes (RAs) into electrophysiologically functional neuron-like cells. RNA sequencing confirmed significant upregulation of neurogenic genes in R/T-MaM-NP-treated RAs, an outcome closely linked to suppression of the Wnt/Notch signaling pathway. Furthermore, R/T-MaM-NPs remodeled the inflammatory microenvironment at the TBI site, alleviated cerebral edema, and enhanced the recovery of cognitive and motor functions in TBI mice.
- 22 January 2026
- Published by Oxford University Press (OUP) in Regenerative Biomaterials
- Vol. 13, rbag059
Open AccessDual-peptide engineered macrophage membrane biomimetic nanosystem via targeting Rg1 delivery for traumatic brain injury therapy
Traumatic brain injury (TBI) induces a detrimental inflammatory microenvironment at the lesion site, which, together with neuronal death and loss, leads to neurological dysfunction. The blood–brain barrier (BBB) further impedes intracerebral drug delivery, posing a major challenge for post-TBI therapy. To overcome this, we developed a brain-targeted biomimetic nanosystem (R/T-MaM-NPs) using an engineered dual-peptide-modified macrophage membrane (MaM). This system encapsulates neuroprotective ginsenoside Rg1 into poly (lactic-co-glycolic acid)-based nanoparticles (NPs). RAW264.7 macrophages were engineered to co-express targeting peptides (RVG and T7) on their membranes; the derived R/T-MaM was then coated onto NPs. The MaM coating conferred high biocompatibility and biosafety, enabling R/T-MaM-NPs to reduce immune clearance and prolong systemic circulation. By leveraging the intrinsic inflammatory chemotaxis of MaM and dual-peptide targeting, the integrated system promoted traversal across the BBB and subsequent accumulation around the cerebral lesion, thereby inducing the transdifferentiation of reactive astrocytes (RAs) into electrophysiologically functional neuron-like cells. RNA sequencing confirmed significant upregulation of neurogenic genes in R/T-MaM-NP-treated RAs, an outcome closely linked to suppression of the Wnt/Notch signaling pathway. Furthermore, R/T-MaM-NPs remodeled the inflammatory microenvironment at the TBI site, alleviated cerebral edema, and enhanced the recovery of cognitive and motor functions in TBI mice.
- Open Access
- 17 December 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (12) , 45176
Protective Effects of Neuron-Derived Quiescin Sulfhydryl Oxidase 1 Protein on Intracerebral Hemorrhage
Background: Intracranial hemorrhage (ICH) poses a serious risk to human health. The shift between pro-inflammatory (M1) and anti-inflammatory (M2) microglial phenotypes is a complex dynamic process. Quiescin sulfhydryl oxidase 1 (QSOX-1) plays a role in protecting cells from damage caused by oxidative stress and in cellular remodeling processes. This study explored how neuron-derived QSOX-1 protein influences the shift in microglial polarization between the M1 and M2 states, and its subsequent impact on nerve function after ICH. Methods: QSOX-1 expression in the ICH mouse model was detected. Neuroinflammation, nerve damage, microglial phenotype, nerve function changes, and related signaling pathways were observed in mouse or cell models treated with QSOX-1. Results: After ICH, mass spectrometry analysis identified 353 differential proteins, of which the key role of QSOX-1 was verified by bioinformatics analysis. QSOX-1 in the ICH model was highly expressed in the neurons. After treatment with recombinant QSOX-1, the ICH model exhibited reduced neuroinflammation and nerve damage, improved nerve function, and a shift in microglia towards predominantly anti-inflammatory (M2) phenotypes. In vitro, QSOX-1 intervention led to reduced inflammation and neuronal cell death. When QSOX-1 expression was upregulated in microglia, the cells primarily shifted towards the M2 phenotype. This shift was accompanied by reduced levels of phosphorylated nuclear factor kappa B (NF-kB) and thioredoxin (TRX)-interacting protein (TXNIP)/NLR family pyrin domain containing 3 (NLRP3) protein, along with increased levels of phosphorylated inhibitor of NF-kB alpha (IkB-α) and TRX. Conclusion: Neuron-derived QSOX-1 protein reduces neuroinflammation and promotes nerve function recovery after ICH by regulating microglia phenotype changes, which may be related to the IkB-α/NF-kB and TRX/TXNIP/NLRP3 axis.
- 17 December 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (12) , 45176
Open AccessProtective Effects of Neuron-Derived Quiescin Sulfhydryl Oxidase 1 Protein on Intracerebral Hemorrhage
Background: Intracranial hemorrhage (ICH) poses a serious risk to human health. The shift between pro-inflammatory (M1) and anti-inflammatory (M2) microglial phenotypes is a complex dynamic process. Quiescin sulfhydryl oxidase 1 (QSOX-1) plays a role in protecting cells from damage caused by oxidative stress and in cellular remodeling processes. This study explored how neuron-derived QSOX-1 protein influences the shift in microglial polarization between the M1 and M2 states, and its subsequent impact on nerve function after ICH. Methods: QSOX-1 expression in the ICH mouse model was detected. Neuroinflammation, nerve damage, microglial phenotype, nerve function changes, and related signaling pathways were observed in mouse or cell models treated with QSOX-1. Results: After ICH, mass spectrometry analysis identified 353 differential proteins, of which the key role of QSOX-1 was verified by bioinformatics analysis. QSOX-1 in the ICH model was highly expressed in the neurons. After treatment with recombinant QSOX-1, the ICH model exhibited reduced neuroinflammation and nerve damage, improved nerve function, and a shift in microglia towards predominantly anti-inflammatory (M2) phenotypes. In vitro, QSOX-1 intervention led to reduced inflammation and neuronal cell death. When QSOX-1 expression was upregulated in microglia, the cells primarily shifted towards the M2 phenotype. This shift was accompanied by reduced levels of phosphorylated nuclear factor kappa B (NF-kB) and thioredoxin (TRX)-interacting protein (TXNIP)/NLR family pyrin domain containing 3 (NLRP3) protein, along with increased levels of phosphorylated inhibitor of NF-kB alpha (IkB-α) and TRX. Conclusion: Neuron-derived QSOX-1 protein reduces neuroinflammation and promotes nerve function recovery after ICH by regulating microglia phenotype changes, which may be related to the IkB-α/NF-kB and TRX/TXNIP/NLRP3 axis.
- Open Access
- 6 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1666522
Advances in etiology, pathophysiology, diagnosis, and management of lymphedema: a comprehensive review
Lymphedema is a chronic disorder of impaired lymphatic transport that leads to fluid accumulation, fibrosis, and adipose expansion. It presents as primary disease, caused by genetic defects in lymphatic development, or as secondary disease after surgery, radiotherapy, infection, trauma, or malignancy. Recent studies have broadened the genetic basis of primary forms and clarified host and treatment-related risks for secondary forms. Mechanistic insights show that lymphatic stasis drives inflammation, fibrosis, and hypoxia, which remodel the microenvironment and reinforce lymphatic failure. Advances in imaging, including lymphoscintigraphy, indocyanine green lymphography, and magnetic resonance lymphangiography, enable earlier and more accurate diagnosis. Conservative treatment with complete decongestive therapy remains standard, while microsurgical techniques such as lymphaticovenous anastomosis and vascularized lymph node transfer expand options. Emerging pharmacologic strategies that target immune and fibrotic pathways show promise. This review summarizes current progress and highlights opportunities for precision interventions to improve outcomes.
- 6 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1666522
Open AccessAdvances in etiology, pathophysiology, diagnosis, and management of lymphedema: a comprehensive review
Lymphedema is a chronic disorder of impaired lymphatic transport that leads to fluid accumulation, fibrosis, and adipose expansion. It presents as primary disease, caused by genetic defects in lymphatic development, or as secondary disease after surgery, radiotherapy, infection, trauma, or malignancy. Recent studies have broadened the genetic basis of primary forms and clarified host and treatment-related risks for secondary forms. Mechanistic insights show that lymphatic stasis drives inflammation, fibrosis, and hypoxia, which remodel the microenvironment and reinforce lymphatic failure. Advances in imaging, including lymphoscintigraphy, indocyanine green lymphography, and magnetic resonance lymphangiography, enable earlier and more accurate diagnosis. Conservative treatment with complete decongestive therapy remains standard, while microsurgical techniques such as lymphaticovenous anastomosis and vascularized lymph node transfer expand options. Emerging pharmacologic strategies that target immune and fibrotic pathways show promise. This review summarizes current progress and highlights opportunities for precision interventions to improve outcomes.
- Open Access
- 27 May 2025
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 19, 1559549
Visualization of subthalamic nucleus on susceptibility weighted imaging and the verification of accuracy by microelectrode recording
Objective: To investigate the advantages of susceptibility weighted imaging (SWI) for visualizing the subthalamic nucleus (STN) and to verify the accuracy of this method by microelectrode recordings (MERs) and deep brain stimulation (DBS).Methods: We included 42 patients with Parkinson’s disease who underwent STN-DBS in our center. The bilateral STN (n = 84) was visualized on preoperative 3-T T2-weighted imaging (T2w) and SWI and compared using a 4-point scale. The contrast-to-noise ratio of STN was calculated and compared between two images. The dorsoventral borders of the STN on SWI and T2w were measured and compared using data recorded by intraoperative MERs.Results: The visualization scores for the STN and contrast-to-noise ratio of STN relative to the zona incerta and substantia nigra were significantly higher on SWI than on T2w images (p < 0.05). There was no significant difference in the location of the dorsal and ventral borders of the STN visualized by SWI when compared with MER data (p > 0.05). Errors for the dorsal and ventral borders of SWI-STN, as verified by MER (0.56 ± 0.32 mm and 0.72 ± 0.33 mm, respectively) were significantly lower than errors on T2w (0.75 ± 0.33 mm and 0.82 ± 0.45 mm for the dorsal and ventral borders, respectively) (p < 0.05).Conclusion: 3-T SWI was a superior method for delineating the STN than conventional T2w. When applying this method, the dorsoventral SWI-STN border coincided reliably with the physiological border determined by MERs. Direct targeting of the STN using SWI can help optimize preoperative target localization, trajectory planning, and postoperative programming.
- 27 May 2025
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 19, 1559549
Open AccessVisualization of subthalamic nucleus on susceptibility weighted imaging and the verification of accuracy by microelectrode recording
Objective: To investigate the advantages of susceptibility weighted imaging (SWI) for visualizing the subthalamic nucleus (STN) and to verify the accuracy of this method by microelectrode recordings (MERs) and deep brain stimulation (DBS).Methods: We included 42 patients with Parkinson’s disease who underwent STN-DBS in our center. The bilateral STN (n = 84) was visualized on preoperative 3-T T2-weighted imaging (T2w) and SWI and compared using a 4-point scale. The contrast-to-noise ratio of STN was calculated and compared between two images. The dorsoventral borders of the STN on SWI and T2w were measured and compared using data recorded by intraoperative MERs.Results: The visualization scores for the STN and contrast-to-noise ratio of STN relative to the zona incerta and substantia nigra were significantly higher on SWI than on T2w images (p < 0.05). There was no significant difference in the location of the dorsal and ventral borders of the STN visualized by SWI when compared with MER data (p > 0.05). Errors for the dorsal and ventral borders of SWI-STN, as verified by MER (0.56 ± 0.32 mm and 0.72 ± 0.33 mm, respectively) were significantly lower than errors on T2w (0.75 ± 0.33 mm and 0.82 ± 0.45 mm for the dorsal and ventral borders, respectively) (p < 0.05).Conclusion: 3-T SWI was a superior method for delineating the STN than conventional T2w. When applying this method, the dorsoventral SWI-STN border coincided reliably with the physiological border determined by MERs. Direct targeting of the STN using SWI can help optimize preoperative target localization, trajectory planning, and postoperative programming.
- Top Cited PapersOpen Access
- 27 September 2024
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 16, 1459025
The role of PI3K signaling pathway in Alzheimer’s disease
Alzheimer’s disease (AD) is a debilitating progressively neurodegenerative disease. The best-characterized hallmark of AD, which is marked by behavioral alterations and cognitive deficits, is the aggregation of deposition of amyloid-beta (Aβ) and hyper-phosphorylated microtubule-associated protein Tau. Despite decades of experimental progress, the control rate of AD remains poor, and more precise deciphering is needed for potential therapeutic targets and signaling pathways involved. In recent years, phosphoinositide 3-kinase (PI3K) and Akt have been recognized for their role in the neuroprotective effect of various agents, and glycogen synthase kinase 3 (GSK3), a downstream enzyme, is also crucial in the tau phosphorylation and Aβ deposition. An overview of the function of PI3K/Akt pathway in the pathophysiology of AD is provided in this review, along with a discussion of recent developments in the pharmaceuticals and herbal remedies that target the PI3K/Akt signaling pathway. In conclusion, despite the challenges and hurdles, cumulative findings of novel targets and agents in the PI3K/Akt signaling axis are expected to hold promise for advancing AD prevention and treatment.
- 27 September 2024
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 16, 1459025
Top Cited PapersOpen AccessThe role of PI3K signaling pathway in Alzheimer’s disease
Alzheimer’s disease (AD) is a debilitating progressively neurodegenerative disease. The best-characterized hallmark of AD, which is marked by behavioral alterations and cognitive deficits, is the aggregation of deposition of amyloid-beta (Aβ) and hyper-phosphorylated microtubule-associated protein Tau. Despite decades of experimental progress, the control rate of AD remains poor, and more precise deciphering is needed for potential therapeutic targets and signaling pathways involved. In recent years, phosphoinositide 3-kinase (PI3K) and Akt have been recognized for their role in the neuroprotective effect of various agents, and glycogen synthase kinase 3 (GSK3), a downstream enzyme, is also crucial in the tau phosphorylation and Aβ deposition. An overview of the function of PI3K/Akt pathway in the pathophysiology of AD is provided in this review, along with a discussion of recent developments in the pharmaceuticals and herbal remedies that target the PI3K/Akt signaling pathway. In conclusion, despite the challenges and hurdles, cumulative findings of novel targets and agents in the PI3K/Akt signaling axis are expected to hold promise for advancing AD prevention and treatment.
- Open Access
- 12 July 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-19
HAUS Augmin-Like Complex Subunit 1 Influences Tumour Microenvironment and Prognostic Outcomes in Glioma
Background. The expression of HAUS Augmin-like complex subunit 1 (HAUS1), a protein-coding gene, is low in normal samples among various cancers with pan-cancer analysis. The depletion of HAUS1 in cells decreases the G2/M cell compartment and induces apoptosis. However, the detailed expression pattern of HAUS1 and its correlation with immune infiltration in glioma (LGG and GBM) (LGG: low-grade glioma; GBM: glioblastoma) remain unknown. Therefore, in this study, we examined the role and prognostic value of HAUS1 in glioma. Methods. Transcriptional expression data of HAUS1 were collected from the CGGA and TCGA databases. The KaplanMeier analysis, univariate and multivariate Cox analyses, and receiver operating characteristic (ROC) curves were used to analyse the clinical significance of HAUS1 in glioma. The STRING database was used to analyse protein-protein interactions (PPI), and the ClusterProfiler package was used for functional enrichment analysis to examine the possible biological roles of HAUS1. In addition, the HAUS1 promoter methylation modification was analysed using MEXPRESS, and the association between HAUS1 expression and tumour-infiltrating immune cells was investigated using CIBERSORT. Results. Based on the data retrieved from TCGA (703 samples) and CGGA (1018 samples), an elevated expression of HAUS1 was observed in glioma samples, which was associated with poorer survival of patients, unfavourable clinical characteristics, 1p/19q codeletion status, WHO grade, and IDH mutation status. Furthermore, multivariate and univariate Cox analyses revealed that HAUS1 was an independent predictor of glioma. HAUS1 expression level was associated with several tumour-infiltrating immune cells, such as Th2 cells, macrophages, and activated dendritic cells. The outcomes of ROC curve analysis showed that HAUS1 was good to prognosticate immune infiltrating levels in glioma with a higher area under the curve (AUC) value (AUC=0.974). Conclusions. HAUS1 was upregulated and served as a biomarker for poor prognosis in patients with glioma. High HAUS1 expression was associated with several tumour-infiltrating immune cells such as Th2 cells, macrophages, and activated dendritic cells, which had high infiltration levels. Therefore, these findings suggest that HAUS1 is a potential biomarker for predicting the prognosis of patients with glioma and plays a pivotal role in immune infiltration in glioma.
- 12 July 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-19
Open AccessHAUS Augmin-Like Complex Subunit 1 Influences Tumour Microenvironment and Prognostic Outcomes in Glioma
Background. The expression of HAUS Augmin-like complex subunit 1 (HAUS1), a protein-coding gene, is low in normal samples among various cancers with pan-cancer analysis. The depletion of HAUS1 in cells decreases the G2/M cell compartment and induces apoptosis. However, the detailed expression pattern of HAUS1 and its correlation with immune infiltration in glioma (LGG and GBM) (LGG: low-grade glioma; GBM: glioblastoma) remain unknown. Therefore, in this study, we examined the role and prognostic value of HAUS1 in glioma. Methods. Transcriptional expression data of HAUS1 were collected from the CGGA and TCGA databases. The KaplanMeier analysis, univariate and multivariate Cox analyses, and receiver operating characteristic (ROC) curves were used to analyse the clinical significance of HAUS1 in glioma. The STRING database was used to analyse protein-protein interactions (PPI), and the ClusterProfiler package was used for functional enrichment analysis to examine the possible biological roles of HAUS1. In addition, the HAUS1 promoter methylation modification was analysed using MEXPRESS, and the association between HAUS1 expression and tumour-infiltrating immune cells was investigated using CIBERSORT. Results. Based on the data retrieved from TCGA (703 samples) and CGGA (1018 samples), an elevated expression of HAUS1 was observed in glioma samples, which was associated with poorer survival of patients, unfavourable clinical characteristics, 1p/19q codeletion status, WHO grade, and IDH mutation status. Furthermore, multivariate and univariate Cox analyses revealed that HAUS1 was an independent predictor of glioma. HAUS1 expression level was associated with several tumour-infiltrating immune cells, such as Th2 cells, macrophages, and activated dendritic cells. The outcomes of ROC curve analysis showed that HAUS1 was good to prognosticate immune infiltrating levels in glioma with a higher area under the curve (AUC) value (AUC=0.974). Conclusions. HAUS1 was upregulated and served as a biomarker for poor prognosis in patients with glioma. High HAUS1 expression was associated with several tumour-infiltrating immune cells such as Th2 cells, macrophages, and activated dendritic cells, which had high infiltration levels. Therefore, these findings suggest that HAUS1 is a potential biomarker for predicting the prognosis of patients with glioma and plays a pivotal role in immune infiltration in glioma.
- 1 November 2019
- Published by Elsevier in Brain Research Bulletin
- Vol. 153, 171-180
Hippocampal PPARα is involved in the antidepressant-like effects of venlafaxine in mice
- 1 November 2019
- Published by Elsevier in Brain Research Bulletin
- Vol. 153, 171-180
Hippocampal PPARα is involved in the antidepressant-like effects of venlafaxine in mice
- 17 June 2016
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 37 (3) , 527-536
The O-GlcNAc Modification of CDK5 Involved in Neuronal Apoptosis Following In Vitro Intracerebral Hemorrhage
Contrary to cell cycle-associated cyclin-dependent kinases, CDK5 is best known for its regulation of signaling processes in regulating mammalian CNS development. Studies of CDK5 have focused on its phosphorylation, although the diversity of CDK5 functions in the brain suggests additional forms of regulation. Here we expanded on the functional roles of CDK5 glycosylation in neurons. We showed that CDK5 was dynamically modified with O-GlcNAc in response to neuronal activity and that glycosylation represses CDK5-dependent apoptosis by impairing its association with p53 pathway. Blocking glycosylation of CDK5 alters cellular function and increases neuronal apoptosis in the cell model of the ICH. Our findings demonstrated a new role for O-glycosylation in neuronal apoptosis and provided a mechanistic understanding of how glycosylation contributes to critical neuronal functions. Moreover, we identified a previously unknown mechanism for the regulation of activity-dependent gene expression, neural development, and apoptosis.
- 17 June 2016
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 37 (3) , 527-536
The O-GlcNAc Modification of CDK5 Involved in Neuronal Apoptosis Following In Vitro Intracerebral Hemorrhage
Contrary to cell cycle-associated cyclin-dependent kinases, CDK5 is best known for its regulation of signaling processes in regulating mammalian CNS development. Studies of CDK5 have focused on its phosphorylation, although the diversity of CDK5 functions in the brain suggests additional forms of regulation. Here we expanded on the functional roles of CDK5 glycosylation in neurons. We showed that CDK5 was dynamically modified with O-GlcNAc in response to neuronal activity and that glycosylation represses CDK5-dependent apoptosis by impairing its association with p53 pathway. Blocking glycosylation of CDK5 alters cellular function and increases neuronal apoptosis in the cell model of the ICH. Our findings demonstrated a new role for O-glycosylation in neuronal apoptosis and provided a mechanistic understanding of how glycosylation contributes to critical neuronal functions. Moreover, we identified a previously unknown mechanism for the regulation of activity-dependent gene expression, neural development, and apoptosis.